Clarifying Cannabis From THCA Loopholes to Schedule III Shifts

Clarifying Cannabis From THCA Loopholes to Schedule III Shifts

Author: Cannabis Radio June 17, 2026 Duration: 40:52

Dr. Priyanka Sharma, co-CEO of Kazmira Therapeutics and fellow co-CEO Pulak Sharma, cut through the confusion surrounding the rapidly evolving cannabis and hemp sectors. She clarifies the critical distinction between THCA—the non-intoxicating precursor that converts to THC upon heating—and delta-9 THC, noting that current marketing often masks the potential intoxicating effects of heated THCA products.

Dr. Sharma also unpacks the implications of the Schedule III reclassification, explaining why it creates a distinct "two-lane system" for medical cannabis versus industrial hemp rather than a blanket regulatory change.



Advertising Inquiries: https://redcircle.com/brands

Privacy & Opt-Out: https://redcircle.com/privacy

There’s a lot more to the cannabis industry than what grows in the field. Blunt Business, from Cannabis Radio, digs into the complex reality of building and running a company in this fast-moving space. We’re talking about the real work behind the scenes-supply chain logistics, regulatory hurdles, branding in a crowded market, and managing teams in a unique cultural environment. Each episode brings together voices who are actually doing the job, from executives steering multi-state operations to entrepreneurs who just opened their first dispensary. You’ll hear candid roundtable discussions where strategies are debated, and interviews that get into the specifics of leadership and finance without the hype. This isn’t about advocacy or culture; it’s a practical look at the mechanics of a profitable, high-stakes business. Tune in for a podcast that cuts through the smoke and offers tangible insights you can apply, whether you’re an investor, a manager, or building your own venture from the ground up.
Author: Language: English Episodes: 50

Blunt Business
Podcast Episodes
Can Las Vegas Cash In on the Cannabis Reclassification? [not-audio_url] [/not-audio_url]

Duration: 31:16
The potential move to Schedule III presents a massive financial opportunity for "Sin City," yet current local friction threatens to stall that momentum. As the federal government nears reclassification, the industry is a…
A Psychedelic and Cannabis Research Revolution On the Horizon? [not-audio_url] [/not-audio_url]

Duration: 29:28
This episode of Blunt Business explores a significant shift in federal drug policy following a new executive order aimed at accelerating research into psychedelics like LSD, psilocybin, and ibogaine for treating mental h…
4/20 Fortune: Critics Say High-Stakes Holiday Losing Its Edge? [not-audio_url] [/not-audio_url]

Duration: 24:45
As the legal landscape evolves, the traditional 4/20 retail boom is showing signs of cooling, with some markets seeing higher sales during the surrounding week than on the holiday itself due to aggressive discounting and…
Inside New York’s Five-Year Cannabis Chronicle [not-audio_url] [/not-audio_url]

Duration: 29:51
In this episode of The Blunt Business, the discussion dives deep into the complex landscape of the New York cannabis market as it hits its five-year legalization anniversary. While Governor Kathy Hochul lauds the state’s…
The Cannabis Business CLIMB or Cannabis for Healthy Livers [not-audio_url] [/not-audio_url]

Duration: 17:24
Blunt Business dives into the shifting landscape of American cannabis, from the halls of Congress to the microscopic world of medical research. We break down the newly proposed CLIMB Act, a bipartisan bill aimed at final…